JP2010502713A - 粘液を通る輸送を増強するための組成物および方法 - Google Patents

粘液を通る輸送を増強するための組成物および方法 Download PDF

Info

Publication number
JP2010502713A
JP2010502713A JP2009527422A JP2009527422A JP2010502713A JP 2010502713 A JP2010502713 A JP 2010502713A JP 2009527422 A JP2009527422 A JP 2009527422A JP 2009527422 A JP2009527422 A JP 2009527422A JP 2010502713 A JP2010502713 A JP 2010502713A
Authority
JP
Japan
Prior art keywords
particles
particle
mucus
composition
surface modifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009527422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502713A5 (cg-RX-API-DMAC10.html
Inventor
ジャスティン ヘインズ，
サミュエル ケー． レイ，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38945776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010502713(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2010502713A publication Critical patent/JP2010502713A/ja
Publication of JP2010502713A5 publication Critical patent/JP2010502713A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Walking Sticks, Umbrellas, And Fans (AREA)
JP2009527422A 2006-09-08 2007-09-07 粘液を通る輸送を増強するための組成物および方法 Withdrawn JP2010502713A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84328206P 2006-09-08 2006-09-08
PCT/US2007/019522 WO2008030557A2 (en) 2006-09-08 2007-09-07 Compositions and methods for enhancing transport through mucus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013110583A Division JP2013163697A (ja) 2006-09-08 2013-05-27 粘液を通る輸送を増強するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2010502713A true JP2010502713A (ja) 2010-01-28
JP2010502713A5 JP2010502713A5 (cg-RX-API-DMAC10.html) 2011-10-27

Family

ID=38945776

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009527422A Withdrawn JP2010502713A (ja) 2006-09-08 2007-09-07 粘液を通る輸送を増強するための組成物および方法
JP2013110583A Withdrawn JP2013163697A (ja) 2006-09-08 2013-05-27 粘液を通る輸送を増強するための組成物および方法
JP2014256264A Active JP6297481B2 (ja) 2006-09-08 2014-12-18 粘液を通る輸送を増強するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013110583A Withdrawn JP2013163697A (ja) 2006-09-08 2013-05-27 粘液を通る輸送を増強するための組成物および方法
JP2014256264A Active JP6297481B2 (ja) 2006-09-08 2014-12-18 粘液を通る輸送を増強するための組成物および方法

Country Status (9)

Country Link
US (6) US20100215580A1 (cg-RX-API-DMAC10.html)
EP (1) EP2061433B1 (cg-RX-API-DMAC10.html)
JP (3) JP2010502713A (cg-RX-API-DMAC10.html)
AT (1) ATE498393T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007292902B8 (cg-RX-API-DMAC10.html)
CA (1) CA2663003C (cg-RX-API-DMAC10.html)
DE (1) DE602007012559D1 (cg-RX-API-DMAC10.html)
ES (1) ES2360538T3 (cg-RX-API-DMAC10.html)
WO (1) WO2008030557A2 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515992A (ja) * 2012-05-04 2015-06-04 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
JP2015515990A (ja) * 2012-05-03 2015-06-04 カラ ファーマシューティカルズ インコーポレイテッド 改善された粘膜輸送を示す医薬用ナノ粒子
JP2015519330A (ja) * 2012-05-03 2015-07-09 カラ ファーマシューティカルズ インコーポレイテッド 改善された粘膜輸送を示す医薬用ナノ粒子
JP2022009979A (ja) * 2013-11-02 2022-01-14 カラ ファーマシューティカルズ インコーポレイテッド 医薬組成物

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
MX2010008902A (es) * 2008-02-18 2011-03-02 Csir Transportadores de nanoparticulas para administracion de farmacos y procedimiento para producir las mismas.
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN102958556B (zh) 2010-04-28 2017-02-15 金伯利-克拉克环球有限公司 细胞相互作用增强的纳米图案化医疗装置
US9586044B2 (en) 2010-04-28 2017-03-07 Kimberly-Clark Worldwide, Inc. Method for increasing the permeability of an epithelial barrier
WO2011135531A2 (en) 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. MEDICAL DEVICES FOR DELIVERY OF siRNA
EP2563450B1 (en) 2010-04-28 2017-07-26 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012039979A2 (en) * 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
EP3542851B1 (en) 2011-10-27 2021-12-15 Sorrento Therapeutics, Inc. Implantable devices for delivery of bioactive agents
BR112014009713A2 (pt) 2011-10-27 2017-04-18 Kimberly Clark Co administração transdérmica de agentes bioativos de alta viscosidade
CA2859046C (en) * 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US9415020B2 (en) * 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9895437B2 (en) * 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US10864219B2 (en) * 2012-05-03 2020-12-15 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
EP3434774A1 (en) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016086026A1 (en) 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
WO2016094710A1 (en) 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1 -amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
WO2016094880A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
MX2017007873A (es) 2014-12-15 2017-11-06 Univ Johns Hopkins Formulaciones de sunitinib y metodos para uso de las mismas en el tratamiento de trastornos oculares.
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US20180271970A1 (en) 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
PE20181531A1 (es) 2015-10-22 2018-09-26 Modernatx Inc Vacuna del virus herpes simple
MA46023A (fr) 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
WO2017075565A1 (en) * 2015-10-30 2017-05-04 The Johns Hopkins University Mucus penetrating particles with high molecular weight and dense coatings
US10441548B2 (en) 2015-11-12 2019-10-15 Graybug Vision, Inc. Aggregating microparticles for medical therapy
SMT202200310T1 (it) 2015-12-23 2022-09-14 Modernatx Inc Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
KR101741977B1 (ko) * 2016-04-26 2017-05-31 한국교통대학교산학협력단 경구 투여용 유전자 전달을 위한 나노입자 및 이를 포함하는 약학 조성물
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
MX2019011242A (es) 2017-03-23 2020-01-21 Graybug Vision Inc Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
WO2020028909A1 (en) * 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
US20220175690A1 (en) * 2020-11-17 2022-06-09 Phosphorex, Inc. Novel drug delivery composition and process for blood-brain barrier crossing
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508020A (ja) * 1997-07-03 2002-03-12 ウエスト・ファーマシューティカルズ・サービシーズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド ポリエチレングリコールとキトサンの複合体
US20050101676A1 (en) * 2003-08-07 2005-05-12 Fahl William E. Amino thiol compounds and compositions for use in conjunction with cancer therapy
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CA2564982A1 (en) * 2004-04-29 2005-11-10 Instituto Cientifico Y Tecnologico De Navarra, S.A. Pegylated nanoparticles

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
CH671402A5 (cg-RX-API-DMAC10.html) * 1985-10-02 1989-08-31 Sandoz Ag
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4789724A (en) * 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US4868274A (en) * 1988-05-23 1989-09-19 Hoechst Celanese Corp. Polyanhydride from carboxy aryloxy alkanoic acid
US4999417A (en) * 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6355271B1 (en) * 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US20040102197A1 (en) * 1999-09-30 2004-05-27 Dietz Timothy Alan Dynamic web page construction based on determination of client device location
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB2370839A (en) * 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
AU2002322289A1 (en) * 2001-06-22 2003-01-08 Johns Hopkins University School Of Medicine Biodegradable polymer coompositions
GB0200289D0 (en) * 2002-01-08 2002-02-20 Koninkl Philips Electronics Nv Switched-current integrator
AU2006220411B2 (en) * 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
MXPA05003162A (es) * 2002-09-26 2005-07-05 Yamanouchi Pharma Co Ltd Agentes mejoradores de absorbibilidad de droga.
JP2006516262A (ja) * 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7060299B2 (en) * 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
CA2555335A1 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
WO2006080951A2 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
JP2008513363A (ja) * 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20090155182A1 (en) * 2005-12-09 2009-06-18 Invitrogen Corporation Optical in vivo imaging contrast agents and methods of use
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
WO2008033924A2 (en) * 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20090226531A1 (en) * 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
AU2011323250B2 (en) * 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508020A (ja) * 1997-07-03 2002-03-12 ウエスト・ファーマシューティカルズ・サービシーズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド ポリエチレングリコールとキトサンの複合体
US20050101676A1 (en) * 2003-08-07 2005-05-12 Fahl William E. Amino thiol compounds and compositions for use in conjunction with cancer therapy
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CA2564982A1 (en) * 2004-04-29 2005-11-10 Instituto Cientifico Y Tecnologico De Navarra, S.A. Pegylated nanoparticles

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515990A (ja) * 2012-05-03 2015-06-04 カラ ファーマシューティカルズ インコーポレイテッド 改善された粘膜輸送を示す医薬用ナノ粒子
JP2015519330A (ja) * 2012-05-03 2015-07-09 カラ ファーマシューティカルズ インコーポレイテッド 改善された粘膜輸送を示す医薬用ナノ粒子
JP2018162284A (ja) * 2012-05-03 2018-10-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
JP2015515992A (ja) * 2012-05-04 2015-06-04 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
JP2022009979A (ja) * 2013-11-02 2022-01-14 カラ ファーマシューティカルズ インコーポレイテッド 医薬組成物
JP7368661B2 (ja) 2013-11-02 2023-10-25 アルコン インコーポレイティド 医薬組成物

Also Published As

Publication number Publication date
WO2008030557A9 (en) 2008-06-26
JP2013163697A (ja) 2013-08-22
JP6297481B2 (ja) 2018-03-20
EP2061433A2 (en) 2009-05-27
US20180264135A1 (en) 2018-09-20
AU2007292902B2 (en) 2013-08-22
CA2663003A1 (en) 2008-03-13
JP2015057438A (ja) 2015-03-26
EP2061433B1 (en) 2011-02-16
US20100215580A1 (en) 2010-08-26
US20200345864A1 (en) 2020-11-05
US20170095566A1 (en) 2017-04-06
WO2008030557A2 (en) 2008-03-13
ATE498393T1 (de) 2011-03-15
WO2008030557A3 (en) 2008-05-02
DE602007012559D1 (de) 2011-03-31
US20130164343A1 (en) 2013-06-27
AU2007292902A8 (en) 2013-09-05
ES2360538T3 (es) 2011-06-06
CA2663003C (en) 2018-02-13
AU2007292902B8 (en) 2013-09-05
AU2007292902A1 (en) 2008-03-13
US20230108636A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
JP6297481B2 (ja) 粘液を通る輸送を増強するための組成物および方法
US20210052507A1 (en) Drugs and gene carrier particles that rapidly move through mucous barriers
Osman et al. Surface modification of nano‐drug delivery systems for enhancing antibiotic delivery and activity
Yao et al. Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity
US9649391B2 (en) Particles with multiple functionalized surface domains
Issa et al. Chitosan and the mucosal delivery of biotechnology drugs
EP3313527B1 (en) Anticancer drug-containing plant virus particles
JP2011516443A (ja) 活性薬剤の、肺への標的化送達のためのナノ粒子
JP2009508936A (ja) 活性物質の標的化送達用ナノ粒子
CA2859046A1 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
JP2016510001A (ja) シスプラチン充填キトサンナノ粒子を含む標的化された頬側送達
EP2706354A1 (en) Multifunctionalized materials
AU2011205629B2 (en) Methods and compositions for nanoparticle-mediated cancer cell-targeted delivery
Singh et al. Engineered nanomaterials for immunomodulation: A review
Vaidya et al. Bioconjugation of polymers: a novel platform for targeted drug delivery
Behnke et al. Knowledge-based design of multifunctional polymeric nanoparticles
Gauraha et al. Protein delivery by nanoparticles
Selim et al. Drug Delivery Using Green Nanotechnology
CN121371212A (zh) 一种心脏靶向纳米颗粒及其制备方法和应用
Tang Biodegradable drug-loaded mucus penetrating nanoparticles for lung cancer
Furtado et al. Article type: Review Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
WO2016161102A1 (en) A supramolecular chitosan complex drug delivery platform

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130322

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140520

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140613

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141224